CN120754114A - 用于改进nrf2激活的组合物和其使用方法 - Google Patents

用于改进nrf2激活的组合物和其使用方法

Info

Publication number
CN120754114A
CN120754114A CN202510745791.9A CN202510745791A CN120754114A CN 120754114 A CN120754114 A CN 120754114A CN 202510745791 A CN202510745791 A CN 202510745791A CN 120754114 A CN120754114 A CN 120754114A
Authority
CN
China
Prior art keywords
extract
luteolin
composition
rosemary
ginger
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510745791.9A
Other languages
English (en)
Chinese (zh)
Inventor
布鲁克斯·迈克尔·海伯特松
乔·米尔顿·麦考德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pathways Bioscience LLC
Original Assignee
Pathways Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathways Bioscience LLC filed Critical Pathways Bioscience LLC
Publication of CN120754114A publication Critical patent/CN120754114A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN202510745791.9A 2015-09-03 2016-09-02 用于改进nrf2激活的组合物和其使用方法 Pending CN120754114A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562214175P 2015-09-03 2015-09-03
US62/214,175 2015-09-03
US201662355810P 2016-06-28 2016-06-28
US62/355,810 2016-06-28
CN201680050947.0A CN108136209A (zh) 2015-09-03 2016-09-02 用于改进nrf2激活的组合物和其使用方法
PCT/US2016/050292 WO2017041054A1 (en) 2015-09-03 2016-09-02 Compositions for improved nrf2 activation and methods of their use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680050947.0A Division CN108136209A (zh) 2015-09-03 2016-09-02 用于改进nrf2激活的组合物和其使用方法

Publications (1)

Publication Number Publication Date
CN120754114A true CN120754114A (zh) 2025-10-10

Family

ID=58188643

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510745791.9A Pending CN120754114A (zh) 2015-09-03 2016-09-02 用于改进nrf2激活的组合物和其使用方法
CN201680050947.0A Pending CN108136209A (zh) 2015-09-03 2016-09-02 用于改进nrf2激活的组合物和其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680050947.0A Pending CN108136209A (zh) 2015-09-03 2016-09-02 用于改进nrf2激活的组合物和其使用方法

Country Status (9)

Country Link
US (1) US11413269B2 (enExample)
JP (1) JP6901787B2 (enExample)
CN (2) CN120754114A (enExample)
CL (1) CL2018000573A1 (enExample)
CO (1) CO2018003454A2 (enExample)
HK (1) HK1256480A1 (enExample)
MX (2) MX394479B (enExample)
PE (1) PE20190380A1 (enExample)
WO (1) WO2017041054A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220354916A1 (en) * 2015-09-03 2022-11-10 Pathways Bioscience, Llc Compositions for improved nrf2 activation and methods of their use
US10993981B2 (en) * 2016-07-11 2021-05-04 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organiation (Aro), (Volcani Center) Compositions for treatment of follicular tonsillitis using an emulsion based on rosemary extract and oregano essential oil
CN110545831A (zh) * 2017-04-27 2019-12-06 帝斯曼知识产权资产管理有限公司 Withania somnifera提取物提供针对空气污染相关疾病的保护的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888514A (en) * 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation
US9265808B2 (en) * 2004-03-23 2016-02-23 Lifeline Nutraceuticals Corporation Compositions for alleviating inflammation and oxidative stress in a mammal
WO2006073042A1 (ja) * 2005-01-05 2006-07-13 Toagosei Co., Ltd. Ｎｒｆ２依存遺伝子の活性化剤
CN101460185A (zh) * 2006-04-03 2009-06-17 雀巢产品技术援助有限公司 用于促进骨生长和维持骨健康的营养组合物及与其有关的方法
US8142806B2 (en) 2008-03-10 2012-03-27 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
CN102164508B (zh) 2008-07-31 2015-04-01 嘉康利公司 具有增加的抗氧化活性的麝香葡萄组合物
JP2011057654A (ja) * 2009-09-14 2011-03-24 Iwate Univ メタボリックシンドローム治療又は予防薬、及び脂肪細胞分化抑制方法
CA2785581A1 (en) 2009-12-24 2011-06-30 Stanley Kubow Compositions and methods for preventing and treating diseases and environmentally induced health disorders
KR101254847B1 (ko) * 2010-05-27 2013-04-15 한림대학교 산학협력단 실리비닌(silibinin)을 포함하는 골다공증 치료 및 예방용 조성물
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
CN104540513B (zh) * 2012-01-16 2019-04-05 赫克托·德·杰休斯·维莱斯-里韦拉 用于治疗与关节疾病相关疼痛的植物组合物
JP2013209351A (ja) 2012-03-30 2013-10-10 Sunstar Inc 抗酸化機能亢進剤
US20140287071A1 (en) * 2013-01-17 2014-09-25 Lifevantage Corporation Veterinary supplements
WO2014151891A1 (en) * 2013-03-14 2014-09-25 Walley Darlene Topical products
AU2014291615B2 (en) * 2013-07-17 2019-09-26 Council Of Scientific & Industrial Research Pharmaceutical composition for the treatment of diminution of bone tissue
WO2016037971A1 (en) * 2014-09-08 2016-03-17 Bios Line S.P.A. Compositions comprising glucosinolates precursors of sulforaphane in combination with extracts of rosemary

Also Published As

Publication number Publication date
PE20190380A1 (es) 2019-03-08
HK1256480A1 (zh) 2019-09-27
MX394479B (es) 2025-03-24
CN108136209A (zh) 2018-06-08
JP2018529763A (ja) 2018-10-11
MX2018002743A (es) 2018-06-06
US20180250264A1 (en) 2018-09-06
US11413269B2 (en) 2022-08-16
MX2022009446A (es) 2022-09-05
JP6901787B2 (ja) 2021-07-14
CO2018003454A2 (es) 2018-08-31
WO2017041054A1 (en) 2017-03-09
CL2018000573A1 (es) 2019-01-11

Similar Documents

Publication Publication Date Title
Lu et al. Saikosaponin a and its epimer saikosaponin d exhibit anti-inflammatory activity by suppressing activation of NF-κB signaling pathway
Wu et al. Anti-inflammatory effects of 4′-demethylnobiletin, a major metabolite of nobiletin
KR102459500B1 (ko) 퀘르세틴 배당체를 함유하는 근위축 억제제
Boojar et al. Overview of Silibinin anti-tumor effects
Yang et al. Anti-inflammatory effect of prunetin via the suppression of NF-κB pathway
Wang et al. Recent advances in natural therapeutic approaches for the treatment of cancer
Yang et al. Suppression of LPS‐induced inflammation by chalcone Flavokawain A through activation of Nrf2/ARE‐mediated antioxidant genes and inhibition of ROS/NFκB signaling pathways in primary splenocytes
Xiao et al. Indigo naturalis suppresses colonic oxidative stress and Th1/Th17 responses of DSS‐induced colitis in mice
Treasure et al. Exploring the anti‐inflammatory activity of sulforaphane
Xu et al. Effects of hydroxysafflor yellow A on the activity and mRNA expression of four CYP isozymes in rats
John et al. The metabolic and molecular mechanisms of α-mangostin in cardiometabolic disorders
Vitali et al. Dipotassium glycyrrhizate via HMGB1 or AMPK signaling suppresses oxidative stress during intestinal inflammation
Soliman et al. Protective Impacts of Moringa oleifera Leaf Extract against Methotrexate‐Induced Oxidative Stress and Apoptosis on Mouse Spleen
Xie et al. Comparation of Anti‐Inflammatory and Antioxidantactivities of Curcumin, Tetrahydrocurcuminand Octahydrocurcuminin LPS‐Stimulated RAW264. 7 Macrophages
Wang et al. Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer
Wu et al. Total C-21 steroidal glycosides, isolated from the root tuber of Cynanchum auriculatum Royle ex Wight, attenuate hydrogen peroxide-induced oxidative injury and inflammation in L02 cells
Calis et al. Naringenin prevents inflammation, apoptosis, and DNA damage in potassium oxonate-induced hyperuricemia in rat liver tissue: roles of cytochrome C, NF-κB, caspase-3, and 8-hydroxydeoxyguanosine
Swathi Krishna et al. Dietary foods containing nitric oxide donors can be early curators of SARS‐CoV‐2 infection: A possible role in the immune system
Toma et al. Novel molecular mechanisms by which ginger extract reduces the inflammatory stress in TNFα–activated human endothelial cells; decrease of Ninjurin-1, TNFR1 and NADPH oxidase subunits expression
CN120754114A (zh) 用于改进nrf2激活的组合物和其使用方法
Yadavalli et al. Repurposed drugs in treating glioblastoma multiforme: Clinical trials update
CN102579425B (zh) 鸡血藤提取物及其应用和异甘草素的新用途
US20180271803A1 (en) Compositions and methods for treatment or prevention of oral mucositis
CN101808654A (zh) 提取自棕榈油榨油废液的用于癌症治疗的化合物、其混合物及方法
US7731994B2 (en) Pharmaceutical composition for protecting neurons comprising extract of lithospermum erythrothizon SIEB. ET. Zucc or acetylshikonin isolated therefrom as an effective ingredient

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination